Table Of Contents

1. Introduction

 1.1 Market Definition & Scope

 1.2 Research Assumptions & Abbreviations

 1.3 Research Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032

 2.3 Market Size & Forecast, By Segmentation, 2021–2032

  2.3.1 Market Size By Application

  2.3.2 Market Size By Product

 2.3.3 Market Size By Target

 2.3.4 Market Size By Technology

 2.4 Market Share & Bps Analysis By Region, 2024

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

  3.4.1 Raw Material Suppliers

  3.4.2 Manufacturers

  3.4.3 Distributors/Suppliers

  3.4.4 Customers/End-Users

 3.5 Industry Life Cycle Assessment

 3.6 Parent Market Overview

 3.7 Market Risk Assessment

4. Statistical Insights & Trends Reporting

4.1 Clinical Performance & Efficacy Metrics

4.1.1 Average overall response rate (ORR %) of ADC therapies in clinical trials

4.1.2 Average progression-free survival (PFS, months) achieved by approved ADCs

4.1.3 Average reduction (%) in off-target toxicity compared to conventional chemotherapy

4.2 Adoption & Treatment Trends

4.2.1 Share of ADC adoption by cancer type (breast, hematologic, lung, others) (%)

4.2.2 Year-on-year growth (%) in ADC prescriptions globally

4.2.3 Share of ADCs used as monotherapy vs combination therapy (%)

4.3 R&D & Pipeline Development Metrics

4.3.1 Number of ADCs in preclinical, Phase I, Phase II, and Phase III trials

4.3.2 Share of ADC pipeline by target antigen type (HER2, CD30, TROP2, others) (%)

4.3.3 Average clinical trial success rate (%) for ADCs compared to other oncology drugs

4.4 Cost & Accessibility Benchmarks

4.4.1 Average treatment cost (USD) per patient for ADC therapies

4.4.2 Share of ADC therapies covered under reimbursement programs (by region) (%)

4.4.3 Average reduction (%) in hospital stays or supportive care costs with ADC adoption

5. Antibody Drug Conjugates [ADC] Market Segmental Analysis & Forecast, By Application, 2021 – 2032, Value (USD Billion)

5.1 Introduction

 5.2 Blood Cancer

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2021 – 2032

 5.3 Breast Cancer

 5.4 Urothelial Cancer & Bladder Cancer

 5.5 Other Cancer

6. Antibody Drug Conjugates [ADC] Market Segmental Analysis & Forecast, By Product, 2021 – 2032, Value (USD Billion)

    6.1 Introduction

 6.2 Kadcyla

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2021 – 2032

 6.3 Enhertu

 6.4 Adcetris

 6.5 Trodelvy

 6.6 Polivy

 6.7 Others

7. Antibody Drug Conjugates [ADC] Market Segmental Analysis & Forecast, By Target, 2021 – 2032, Value (USD Billion)

    7.1 Introduction

 7.2 HER2

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2021 – 2032

 7.3 CD22

 7.3 CD30

 7.3 Others

8. Antibody Drug Conjugates [ADC] Market Segmental Analysis & Forecast, By Technology, 2021 – 2032, Value (USD Billion)

    8.1 Introduction

 8.2 Technology Type

  8.2.1 Key Trends

  8.2.2 Market Size & Forecast, 2021 – 2032

 8.3 Linker Technology Type

 8.4 Payload Technology

9. Antibody Drug Conjugates [ADC] Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Billion)

9.1 Introduction

9.2 North America

 9.2.1 Key Trends

 9.2.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032

 9.2.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032

 9.2.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032

 9.2.5 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032

 9.2.6 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Country, 2021 – 2032

  9.2.6.1 USA

  9.2.6.2 Canada

9.3 Europe

 9.3.1 Key Trends

 9.3.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032

 9.3.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032

 9.3.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032

 9.3.5 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032

 9.3.6 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Country, 2021 – 2032

  9.3.6.1 Germany

  9.3.6.2 UK

  9.3.6.3 France

  9.3.6.4 Italy

  9.3.6.5 Spain

  9.3.6.6 Russia

  9.3.6.7 Poland

  9.3.6.8 Rest of Europe

9.4 Asia-Pacific

 9.4.1 Key Trends

 9.4.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032

 9.4.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032

 9.4.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032

 9.4.5 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032

 9.4.6 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Country, 2021 – 2032

  9.4.6.1 China

  9.4.6.2 India

  9.4.6.3 Japan

  9.4.6.4 South Korea

  9.4.6.5 Australia

  9.4.6.6 ASEAN Countries

  9.4.6.7 Rest of Asia-Pacific

9.5 Latin America

 9.5.1 Key Trends

 9.5.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032

 9.5.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032

 9.5.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032

 9.5.5 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032

 9.5.6 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Country, 2021 – 2032

  9.5.6.1 Brazil

  9.5.6.2 Argentina

  9.5.6.3 Mexico

  9.5.6.4 Colombia

  9.5.6.5 Rest of Latin America

9.6 Middle East & Africa

 9.6.1 Key Trends

 9.6.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032

 9.6.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032

 9.6.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032

 9.6.5 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032

 9.6.6 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Country, 2021 – 2032

  9.6.6.1 UAE

  9.6.6.2 Saudi Arabia

  9.6.6.3 Qatar

  9.6.6.4 South Africa

  9.6.6.5 Rest of Middle East & Africa

10. Competitive Landscape

 10.1 Key Players' Positioning

 10.2 Competitive Developments

  10.2.1 Key Strategies Adopted (%), By Key Players, 2024

  10.2.2 Year-Wise Strategies & Development, 2021 – 2025

  10.2.3 Number Of Strategies Adopted By Key Players, 2024

 10.3 Market Share Analysis, 2024

 10.4 Product/Service & Application Benchmarking

  10.4.1 Product/Service Specifications & Features By Key Players

  10.4.2 Product/Service Heatmap By Key Players

  10.4.3 Application Heatmap By Key Players

 10.5 Industry Start-Up & Innovation Landscape

10.6 Key Company Profiles

10.6.1 Genentech.

 10.6.1.1 Company Overview & Snapshot

 10.6.1.2 Product/Service Portfolio

 10.6.1.3 Key Company Financials

 10.6.1.4 SWOT Analysis

10.6.2 Seagen Inc.

10.6.3 AstraZeneca

10.6.4 Daiichi Sankyo

10.6.5 Pfizer

10.6.6 ImmunoGen

10.6.7 Bristol Myers Squibb

10.6.8 Amgen

10.6.9 ADC Therapeutics

10.6.10 MacroGenics

10.6.11 Bayer

10.6.12 Zymeworks

10.6.13 Gilead Sciences

10.6.14 Mersana Therapeutics

10.6.15 Boehringer Ingelheim

10.6.16 Sanofi

10.6.17 Eli Lilly

10.6.18 Janssen Biotech

10.6.19 Roche

10.6.20 Curis Inc.

11. Analyst Recommendations

 11.1 SNS Insider Opportunity Map

 11.2 Industry Low-Hanging Fruit Assessment

 11.3 Market Entry & Growth Strategy

 11.4 Analyst Viewpoint & Suggestions On Market Growth

12. Assumptions

13. Disclaimer

14. Appendix

 14.1 List Of Tables

 14.2 List Of Figures